Skip to content Skip to sidebar Skip to footer

Newsletter

Healthcare Stocks

Oceania Healthcare Soars 16% on Strong FY31 Growth Plan

Oceania Healthcare (ASX/NZX: OCA) surprised the market today with a 16 percent surge after unveiling its 2025 Investor Day presentation. The company laid out a clear, disciplined roadmap to FY31, outlining plans to strengthen its balance sheet, boost operational performance, and scale its aged care and retirement village portfolio across New Zealand. For a stock…

ByCharlie YouldenOctober 8, 2025

PainChek (ASX:PCK): Investors dreamed 2025 would be the year it finally enters the US market, and their dreams are becoming a reality!

PainChek (ASX:PCK) has among the most admirable medical technologies there is, in the form of an app that can detect pain in non-verbal patients. Unfortunately, there has been pain for investors along the way. When it was announced that it was participating in a clinical trial the Morrison government was investing $5m in back in 2019,…

ByNick SundichOctober 8, 2025

Cyclopharm (ASX:CYC): FDA approved for 2 years now, but a lawsuit from 4DX is the latest headache and cause for investor scepticism

Cyclopharm (ASX:CYC) is a rare species - an ASX stock that is approved in the US market. However, its share price has gone in the opposite direction. Cyclopharm has not had as fast an uplift as other companies have had and still makes most of its sales from other jurisdictions. A lawsuit from 4D Medical…

ByNick SundichOctober 8, 2025

Activist investors: Here’s what you need to know about them and 4 famous Australian activists to watch out for

Hear the term 'Activist investors' and you might think of GetUp, the progressive activist group that forced Woolworths to hold an EGM in 2014 in an attempt to limit the maximum bets on poker machines to $1. Or perhaps even of ESG-focused fundies like Australian Ethical (ASX:AEF). The reality is a lot more complicated and…

ByNick SundichOctober 8, 2025

Race Oncology Jumps 23% as Researchers Uncover Key Mechanism Behind Lead Cancer Drug

Race Oncology Soars 23% on Breakthrough Discovery Targeting MYC Race Oncology (ASX: RAC) opened strongly, rising 23 percent after releasing new insights into how its lead cancer drug, bisantrene (RC220 Bisantrene, RCDS1), actually works inside the body. The company’s researchers found that the drug attaches to and stabilises DNA and RNA structures known as…

ByCharlie YouldenOctober 2, 2025

EBR Systems (ASX:EBR): Another heart-focused medtech that has gained FDA approval

Mere days after Artrya (ASX:AYA) obtained FDA approval for its heart-health technology, EBR Systems (ASX:EBR) has achieved that same feat. The company made a surprising 15% plunge on the day of the announcement, and the share price has been nuanced since. However, it is still a >$500m company more than when it first listed. Let's take…

ByNick SundichOctober 1, 2025

Proteomics has launched 2 Promarker tests in a matter on months and is about to launch a 3rd

Proteomics' suite of Promarker tests are all being launched in 2025. The range includes: PromarkerD for DKD which has been launched in Australia and the USA; PromarkerEso for Esophageal cancer which is now commercially available in Australia, and PromarkerEndo for Endometriosis which will be commercialised shortly. Launching 3 tests in a a year is…

ByNick SundichSeptember 26, 2025

Amplia Therapeutics (ASX:ATX): Battling pancreatic cancer with an FAK inhibitor

Amplia Therapeutics (ASX:ATX) is another ASX oncology biotech company, attempting to battle cancer. At first glance, it may not a unique company but when you dig deeper...it is. It is using an 'FAK inhibitor' to fight pancreatic cancer (and potentially other indications down the track). What are the Best ASX Stocks to invest in right now?…

ByNick SundichSeptember 23, 2025

Starpharma (ASX: SPL) Soars 70% on Genentech Deal

Starpharma Lands Genentech Collaboration Starpharma (ASX: SPL) has caught investor attention with a stunning 70 percent share price surge after unveiling a collaboration with global biotech giant Genentech. At the heart of the deal is Starpharma’s DEP platform, which uses dendrimers—tiny, tree-like molecules designed to carry cancer drugs more effectively through the body. By “loading”…

ByCharlie YouldenSeptember 22, 2025

Nexsen: Another ‘point of care diagnostics’ company is about to hit the ASX

There's another company about to join the cohort of ASX biotech stocks and its name is Nexsen. Nexsen is proposed to list on Tuesday October 7, raising $6m at 20c per share, and to have the code NXN. This company has a rapid sensing technology that it will first commercialise to detect Group B Streptococcus…

ByNick SundichSeptember 19, 2025

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Oceania Healthcare Soars 16% on Strong FY31 Growth Plan

PainChek (ASX:PCK): Investors dreamed 2025 would be the year it finally enters the US market, and their dreams are becoming a reality!

Cyclopharm (ASX:CYC): FDA approved for 2 years now, but a lawsuit from 4DX is the latest headache and cause for investor scepticism

Activist investors: Here’s what you need to know about them and 4 famous Australian activists to watch out for

Race Oncology Jumps 23% as Researchers Uncover Key Mechanism Behind Lead Cancer Drug

EBR Systems (ASX:EBR): Another heart-focused medtech that has gained FDA approval

Proteomics has launched 2 Promarker tests in a matter on months and is about to launch a 3rd

Amplia Therapeutics (ASX:ATX): Battling pancreatic cancer with an FAK inhibitor

Starpharma (ASX: SPL) Soars 70% on Genentech Deal

Nexsen: Another ‘point of care diagnostics’ company is about to hit the ASX

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here